Brian Tomlinson, [email protected] These authors have contributed equally to this work and share first authorship ORCID: Brian Tomlinson, orcid.org/0000-0001-6717-5444 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Tirzepatide was initiated at 2.5 mg subcutaneously once weekly and titrated in 2.5 mg increments to reach the minimum effective dose, with maintenance doses ranging from 2.5 to 10 mg/wk (mean maintenance dose, 6 mg/wk)
These effects occur because GLP-1 receptor agonists fundamentally alter digestive processes, particularly gastric emptying rates
Two doses of 10mg in close succession would deliver 20mg to your system, well above the maximum approved dose of 15mg, and would significantly increase side effect risk
For most patients, it is temporary
Gaziano, 2010)